Close Menu
TIMES24H – International Breaking News
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    TIMES24H – International Breaking News
    • Hot!
      • Vietnam
      • Asia
      • Video
    • World
      • PR Newswire
      • Media OutReach Newswire
      • GLOBENEWSWIRE
    • Business
    • Life
      • Lifestyle
      • Recipes
      • Fashion
    • Sport
    • Tech
      • Gadgets
    Media Outreach Newswire
    TIMES24H – International Breaking News
    Home»Breaking News»AstraZeneca antibody cocktail fails to prevent Covid-19 in large trial | World News
    Breaking News

    AstraZeneca antibody cocktail fails to prevent Covid-19 in large trial | World News

    Mike HarrisonBy Mike HarrisonJune 15, 2021No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

    The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms.

    The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

    The Phase III study, which has not been peer-reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.

    Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

    “While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” AstraZeneca Executive Vice President Mene Pangalos said in a statement, referring to the polymerase chain reaction tests which diagnose Covid-19.

    The company is banking on further studies to revive the product’s fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.

    The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

    TARGETED ALTERNATIVES

    AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.

    Similar therapies developed by rivals Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir have been approved by US regulators for treating unhospitalised Covid patients.

    Regeneron is also seeking US authorisation for its therapy as a preventative treatment.

    European regulators have recommended antibody treatments by GSK, Celltrion, Eli Lilly and Regeneron for used in early-stage patients who are at risk of progressing to severe Covid-19. The EU watchdog made the endorsement to support the use by member states ahead of an EU-wide marketing authorisation.

    But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to Covid-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

    The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its Covid-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

    AstraZeneca also said on Tuesday it was in talks with the US government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.

    Shares in the company were largely unchanged on the London Stock Exchange.

    The full results will be submitted for publication in a peer-reviewed medical journal, the company said.

    World News

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    AI Riser Vietnam 2026

    AI Riser Vietnam 2026: Google showcases 10 Vietnamese-built AI projects at Ho Chi Minh City forum

    October 8, 2026

    CCTV+: Xi presents the main directions for developing new quality productive forces

    January 3, 2026
    Hai Sau Sau (266) Partners with Samsung to Drive “One Samsung” Strategy in Vietnam

    Hai Sau Sau (266) Partners with Samsung to Drive “One Samsung” Strategy in Vietnam

    November 13, 2025
    Leave A Reply Cancel Reply

    Latest News
    Cavli Wireless Launches Cavli360, a Collaborative Industry Magazine Connecting the Global IoT Ecosystem

    Cavli Wireless Launches Cavli360, a Collaborative Industry Magazine Connecting the Global IoT Ecosystem

    October 28, 2026
    Envision Energy Unveils AI-powered New Energy System for Mining and Smelting Industry at All Energy Australia

    Envision Energy Unveils AI-powered New Energy System for Mining and Smelting Industry at All Energy Australia

    October 28, 2026
    OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW

    OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW

    October 28, 2026
    ATMOCE Brings Flexible AC Stackable Storage and 15-Year M-ELV Battery Warranty to All Energy Australia 2026

    ATMOCE Brings Flexible AC Stackable Storage and 15-Year M-ELV Battery Warranty to All Energy Australia 2026

    October 27, 2026
    DMCA.com Protection Status
    Facebook X (Twitter) Instagram Pinterest
    TIMES24H
    Global News · Trusted Information · Clear Perspectives
    TIMES24H is a global news platform delivering timely, reliable, and insightful coverage across technology, business, lifestyle, and current affairs. Our mission is to provide readers with clear perspectives and trusted information to navigate a fast-changing world.
    News & Editorial: news@times24h.com
    © 2026 TIMES24H . All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.